Chardan analyst Keay Nakae downgraded Korro Bio (KRRO) to Neutral from Buy with a $7 price target The firm views the negative Phase I/IIa REWRITE trial evaluating KRRO-110 as a “significant setback” for the company. It will require new human clinical data, which now is in 2027, to rebuild investor confidence in Korro’s OPERA design platform, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: